// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

Pancreatic circulating tumor cells as a diagnostic adjunct in pancreatic cancer.

Jacob S Ankeny - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

FOLFERA: A randomized phase II study of irinotecan, 5-fluorouracil (5-FU), and folinic acid (FOLFIRI) with or without addition of the endothelin receptor antagonist (ETAR) zibotentan in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy.

Anne L. Thomas - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Adrucil injection

Circulating tumor cells as predictive marker in panitumumab after progression of cetuximab in Japanese patients with KRAS wild-type metastatic colorectal cancer.

Yoshihito Ohhara - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

panitumumab

An alternative method to detect peritoneal recurrence of gastric cancer: Clinical application of CT colonography.

Kenichi Iwasaki - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Proton reirradiation of locally recurrent pancreatic and ampullary adenocarcinomas.

John Peter Plastaras - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ampullary adenocarcinoma

N/A

Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis.

Paul Basile - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Circulating tumor cells as a possible marker for micrometastatic disease in patients with localized pancreatic cancer.

Rachel D. Aufforth - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary study Circe 07 of the LAP 07 trial.

Florence Huguet - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Gemcitabine

Circulating tumor cells (CTC) in metastatic hepatocellular carcinoma (HCC): Comparison to control patients with nonmalignant liver diseases (NMLD) and exploratory characterization by next generation sequencing (NGS).

Robin Katie Kelley - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer.

Benedikt Engels - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Circulating tumor cells as a possible prognostic tool in newly diagnosed nonmetastatic colorectal cancer-

Loes Scholten - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Cytologic and molecular characterizations of CTC detected in patients with metastatic colorectal carcinomas.

Julien Coget - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.

Satoshi Matsusaka - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

Role of presurgery circulating cancer cells (CTCs) as a potential pronostic factor in patients (pts) with liver surgery (LS) of colorectal cancer (CRC) metastases (M).

Lucia Teijeira - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Clinical significance of circulating tumor cells in blood from patients with advanced or recurrent esophageal cancer.

Motomu Tanaka - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy.

David M. Nanus - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Kim N. Chi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Prednisone

Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).

Jue Wang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cyclophosphamide

Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis.

Daniel Costin Danila - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Use of the slope of the DVH curve for predicting late rectal toxicity in IMRT for patients with localized prostate cancer.

Gilles Crehange - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Copyright © 2026. QuantiNova All rights reserved